Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Desarrollo rápido de biomarcador de suero para la detección precoz del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20141002001
Publicado:
18/01/2016
Caducidad:
24/10/2016
Resumen:
Una empresa londinense ha desarrollado una tecnología y recursos para acelerar la validación de biomarcadores de suero en enfermedades presintomáticas y reducir el período de pruebas de años a meses. La empresa ofrece el uso de la tecnología (algoritmos patentados y biobanco de suero) en biomarcadores para desarrollar métodos de diagnóstico de detección ultrasensibles. Se buscan socios industriales e investigadores académicos que estén estudiando biomarcadores putativos del cáncer con el fin de establecer acuerdos de joint venture o cooperación en materia de investigación.

Details

Tittle:
Accelerated development of serum biomarker for early detection of cancer
Summary:
A London company has developed technology and resources to accelerate the validation of serum biomarkers for pre symptomatic disease reducing trial time from years to months. It is offering the use of its technology (proprietary algorithms and a unique serum biobank) on biomarkers to produce ultra sensitive screening diagnostics. The company is seeking to work with industry and academic researchers who are investigating putative cancer biomarkers in a joint venture or research cooperation.
Description:
Critical problems exist with the discovery and validation of new biomarkers for the early detection of disease. This is exacerbated when the biomarkers are for pre symptomatic disease (to all appearances a perfectly healthy individual). Biomarker levels for the disease might move but to an extent that is within the normal range for the population as a whole. It becomes necessary to examine the movement from the base line of the individual.

Technically it is necessary to carry out longitudinal proof of concept studies to get a biomarker profile and comparison with the individual baseline level. This takes a long time (typically years) and requires a large enough study population to get a significant level of disease occurrence to prove the biomarker. The rarer the disease the greater the test population that is required.

Even with this it is difficult to develop a diagnostic that will meet the necessary regulatory requirements for low levels of false positives and false negatives.

The company has developed proprietary technology in order to exploit to best effect a unique and very large serum biobank, large enough to address a wide range of diseases. The biobank contains 5.5 million samples taken from 202,000, initially cancer free, individuals, 50,000 of whom donated annually for 10 years, plus the associated medical history of the donors. This allows the company to examine biomarkers for diseases that typically develop in this time frame and due to its size some rare diseases as well. It allows retrospective, longitudinal studies to be carried out in matter of months rather than years.

The company is also in possession of a unique technology in the form of algorithms that can be used in the validation of a biomarker as a diagnostic for pre symptomatic disease even with very small changes of titre.

This allows diagnostic tests to be repositioned from diagnosis of symptomatic individuals to screening of a healthy, or high risk population, greatly increasing the market size for the test.

The company wishes to use the biobank, principally, as a resource to identify and validate serum biomarkers for cancer that elevate early in the disease at a point pre symptomatic of illness and ideally earlier than is achievable with other current diagnostics. In order to do this the company wishes to collaborate with researchers who believe they have a serum biomarker that fits these criteria.
Advantages and Innovations:
The company´s proprietary technology and resources can benefit groups researching serum biomarkers for cancer greatly shortening the development time compared with the current established approach to the development of screening diagnostics for pre symptomatic disease. Pre symptomatic disease diagnostics are very difficult to develop currently using commonly used practices.

The profile of the biomarker from pre disease to pre symptomatic disease and beyond can be monitored allowing comparison between individual healthy baselines and the change at pre symptomatic onset of disease. However validating such screening technology for pre symptomatic disease is not possible when the biomarker titres move within the range of the normal population. The kinetics of individual movement from baseline needs to be studied to get a reliable putative diagnostic and justify the ongoing development cost. The company uses a range of in-house algorithms to make this application possible.

Uniquely, along with its algorithms, the company has exclusive access to a biobank of initially cancer free donors, a proportion of whom went on to develop a wide range of cancers, thus permitting a very sensitive disease versus control study to be performed across large test subject groups.

Thus the company is able to carry out a retrospective, longitudinal proof of concept study for serum biomarkers (removing the need to carry out the current established practice of a longitudinal study in real time) vastly reducing the time needed, even in relatively rare cancers. Unlike other resources where the size of the biobank is smaller and the history is shorter, the company´s exclusive resource can effectively carry out a clinical trial where the duration is limited by the time it takes to test the samples.

This combination provides a unique capability to develop a strong technical and commercial case for any industry or academic researcher with suitable serum biomarkers.
Stage of Development:
Field tested/evaluated
IPs:
Exclusive rights
CommeR Statunts Regarding IPR Status:
Exclusive rights to the serum biobank are vested in the company.

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: The company wishes to engage with academic and industry researchers who have identified putative serum biomarkers for cancer and wish to carry out proof of concept studies to determine the efficacy of the biomarker as a diagnostic for presymptomatic disease.

- Specific area of activity of the partner: The partner will be carrying out research using of serum testing, most likely in oncology

- Task to be performed: The partner will need to make available the details of the biomarker and provide support and information about the disease that is the subject of the putative diagnostic.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Dissemination

Restrict dissemination to specific countries:
Albania, Armenia, Austria, Belgium, Bosnia And Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Croatia, Cyprus, Czech_Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Republic Of, Latvia, Lithuania, Luxembourg, Macedonia, The Former Yugoslav Republic Of, Malta, Mexico, Moldova, Republic Of, Montenegro, Morocco, Netherlands, Norway, Poland, Portugal, Republic of Serbia, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom, United States

Keywords

Technology Keywords:
06001001 Bioestadística, epidemiología
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos